Veeva Systems Inc. — Q1 FY2022 Form 10-Q
Reporting period: Three months ended April 30, 2021; comparisons are with the three months ended April 30, 2020 unless otherwise noted. Veeva provides cloud software, data, and services, primarily to the life sciences industry.
Financial performance and liquidity
| Metric | Q1 FY2022 | Prior-year quarter | Change |
|---|---|---|---|
| Total revenue | $433.6 million | $337.1 million | +29% |
| Subscription revenue | $341.1 million | $270.2 million | +26% |
| Professional services and other revenue | $92.5 million | $66.9 million | +38% |
| Gross profit / gross margin | $317.4 million / 73% | $242.2 million / 72% | Margin +1 percentage point |
| Operating income / margin | $128.4 million / 29.6% | $87.6 million / 26.0% | +47% operating income |
| Net income | $115.6 million | $86.6 million | +33% |
| Diluted GAAP EPS | $0.71 | $0.54 | +31% |
| Operating cash flow | $478.4 million | $282.2 million | +70% |
At April 30, 2021, cash and cash equivalents were $1.185 billion and short-term investments were $965.5 million, totaling approximately $2.15 billion. Total liabilities were $777.2 million; these included $59.9 million of operating lease liabilities. The balance sheet reports no borrowings. Management said existing cash, investments, and operating cash flows should cover working capital and capital expenditure needs for at least 12 months. First-quarter operating cash flow is seasonally strong, partly reflecting annual subscription billings and collections and a $301.7 million decrease in accounts receivable.
Subscription gross margin was 85% versus 84%; professional services gross margin was 30% versus 23%. Total revenue mix was 79% subscription and 21% professional services and other. Veeva Vault generated $172.7 million of subscription revenue, up from $127.7 million; Commercial Cloud generated $168.5 million, up from $142.6 million. Stock-based compensation was $48.5 million, compared with $36.9 million.
Material changes and management commentary
- Vault accounted for $45 million of the $71 million year-over-year increase in subscription revenue; Commercial Cloud accounted for $26 million. Management expects Vault to continue increasing as a share of revenue.
- Operating expenses rose 22% to $189.0 million. Research and development increased 34%, primarily on employee compensation and headcount. Management expects operating expenses and stock-based compensation to rise in absolute dollars and operating expenses to increase slightly as a share of revenue.
- The effective tax rate increased to 13.1% from 4.8%, mainly because of higher pretax income and fewer excess tax benefits from equity compensation.
- Management expects revenue growth rates to decline over time. The filing provides no specific quarterly or full-year revenue or earnings guidance in the supplied text.
Outlook, risks, contingencies, and unusual items
- COVID-19: No material negative impact on financial performance had occurred to date, but future effects were uncertain. Remote work and virtual engagement may benefit digital products; a potential reduction of roughly 10% in life sciences sales representatives over the next one to two years could weigh on CRM-related demand. Most employees were still working remotely; most U.S. offices were planned to reopen in July.
- Litigation: In the IQVIA OpenData and Network case, a special master rejected IQVIA’s request for default judgment or dismissal but recommended a permissive adverse-inference instruction concerning certain unpreserved documents and awarded certain fees. Veeva said it appealed the ruling and fee award on June 4, 2021. The company could not estimate a potential gain or loss. The separate Veeva Nitro/IQVIA actions were stayed pending the earlier case. In the Medidata matter, a trial was scheduled for September 20, 2021; Veeva could not estimate a potential loss.
- Commercial commitments: Veeva remained obligated to make at least $35.4 million of purchases under its Salesforce agreement by September 1, 2025. Total disclosed lease obligations were $68.1 million, plus $0.1 million of finance lease obligations.
- Other exposures: Key risks include customer and life sciences industry concentration, competition and restrictions on third-party data use, reliance on Salesforce and other cloud infrastructure providers, cybersecurity and privacy, foreign exchange and interest rates, and the effects of Veeva’s new public-benefit-corporation status. A 100-basis-point interest-rate increase was estimated to reduce investment portfolio market value by $11 million.
- Veeva became a Delaware public benefit corporation on February 1, 2021, with a stated purpose that includes improving productivity in served industries and creating high-quality employment. Its directors must balance stockholder financial interests with stakeholder interests and that purpose.
Important facts for investors to verify
- Whether subscription growth, renewals, and Vault adoption continue to offset expected slower overall growth and potential CRM headwinds.
- Developments in the IQVIA and Medidata cases, including the adverse-inference recommendation, appeal, and potential costs or outcomes.
- Whether higher investment in hiring, product development, infrastructure, and litigation affects margins as management anticipates.
- Changes in cash conversion and deferred revenue: management cautions that quarterly deferred revenue, unbilled receivables, and calculated billings may not reliably indicate future revenue.
- Potential effects of COVID-19, foreign exchange and interest-rate movements, and the PBC governance structure on operations and stockholder interests.